Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 5, 2004, Pages 1201-1203

  Riendeau, Denis ^a   Salem, Myriam ^a   Styhler, Angela ^a   Ouellet, Marc ^a   Mancini, Joseph A ^a   Li, Chun Sing ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DRUG METABOLITE; INDOMETACIN; LOXOPROFEN; ROFECOXIB;

ARTICLE; BLOOD ANALYSIS; BLOOD CHEMISTRY; CIS ISOMER; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; STRUCTURE ANALYSIS; TRANS ISOMER;

EID: 1242271959     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.12.047     Document Type: Article

References (19)

1. Matsuda K., Tanaka Y., Ushiyama S., Ohnishi K., Yamazaki M. Biochem. Pharmacol. 33:1984;2473.
2. Sugimoto M., Kojima T., Asami M., Iizuka Y., Matsuda K. Biochem. Pharmacol. 42:1991;2363.
3. Terada A., Naruto S., Wachi K., Tanaka S., Iizuka Y., Misaka E. J. Med. Chem. 27:1984;212.
4. Naruto S., Tanaka Y., Hayashi R., Terada A. Chem. Pharm. Bull. (Tokyo). 32:1984;258.
5. Tanaka Y., Nishikawa Y., Hayashi R. Chem. Pharm. Bull. (Tokyo). 31:1983;3656.
6. Choo K.S., Kim I.W., Jung J.K., Suh Y.G., Chung S.J., Lee M.H., Shim C.K. J. Pharm. Biomed. Anal. 25:2001;639.
7. Nagashima H., Tanaka Y., Watanabe H., Hayashi R., Kawada K. Chem. Pharm. Bull. (Tokyo). 32:1984;251.
8. Takasaki W., Tanaka Y. Chirality. 4:1992;308.
9. Kawai S., Nishida S., Kato M., Furumaya Y., Okamoto R., Koshino T., Mizushima Y. Eur. J. Pharmacol. 347:1998;87.
10. Synthesis of the eight possible metabolites of loxoprofen has been reported in: Naruto S., Terada A. Chem. Pharm. Bull. 31:1983;4319.
11. trans-Cyclopentanol 5c contaminated with ∼5% of 5b and trans-cyclopentanol 5d contaminated with ∼10% of 5c.
12. 2 levels were then determined by EIA. For details see: Percival M.D., Ouellet M., Vincent C.J., Yergey J.A., Kennedy B.P., O'Neill G.P. Arch. Biochem. Biophys. 315:1994;111.
13. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., Taketo M.M. Cell. 87:1996;803.
14. 2) are measured by immunoassay at the end of the incubation as readouts of COX-2 and COX-1 activity, respectively. For details see: Brideau C., Kargman S., Liu S., Dallob A.L., Ehrich E.W., Rodger I.W., Chan C.C. Inflamm. Res. 45:1996;68.
15. Riendeau D., Percival M.D., Brideau C., Charleson S., Dube D., Ethier D., Falgueyret J.P., Friesen R.W., Gordon R., Greig G., Guay J., Mancini J., Ouellet M., Wong E., Xu L., Boyce S., Visco D., Girard Y., Prasit P., Zamboni R., Rodger I.W., Gresser M., Ford-Hutchinson A.W., Young R.N., Chan C.C. J. Pharmacol. Exp. Ther. 296:2001;558.
16. Caldwell J., Hutt A.J., Fournel-Gigleux S. Biochem. Pharmacol. 37:1988;105.
17. Kawano S., Tsuji S., Hayashi N., Takei Y., Nagano K., Fusamoto H., Kamada T. J. Gastroenterol. Hepatol. 10:1995;81.
18. Arai I., Hamasaka Y., Futaki N., Takahashi S., Yoshikawa K., Higuchi S., Otomo S. Res. Commun. Chem. Pathol. Pharmacol. 81:1993;259.
19. Futaki N., Yoshikawa K., Hamasaka Y., Arai I., Higuchi S., Iizuka H., Otomo S. Gen. Pharmacol. 24:1993;105.